Clinical Trial Update: Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML [Phase 3]

View source ↗

Summary

Phase 3 clinical trial updating a study of Ziftomenib in combination with venetoclax and azacitidine or standard 7+3 induction for newly diagnosed NPM1-mutant o…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Acute Myeloid Leukemia Kmt2a-rearranged
• Acute Myeloid Leukemia Npm1-mutant

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• CYTARABINE (CYTARABINE)
• Daunorubicin (daunorubicin)
• Venetoclax (venetoclax)
• Ziftomenib (ziftomenib)

Snippet

Sponsor: Kura Oncology, Inc. | Conditions: Acute Myeloid Leukemia (AML) | Phase 3 | Status: RECRUITING